Enalapril: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "==Sources==" to "==References==") |
No edit summary |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
''Note: for the active metabolite available in IV, see [[Enalaprilat]]'' | |||
==General== | ==General== | ||
*Type: [[ACE inhibitor]] | *Type: [[ACE inhibitor]] | ||
| Line 5: | Line 6: | ||
General information: | General information: | ||
* Doses > | *Doses > 40mg/day rarely more effective | ||
* Decreased efficacy as | *Decreased efficacy as monotherapy in Black patients | ||
* Obtain Chem 10 if starting in ED to assess renal function | *Obtain Chem 10 if starting in ED to assess renal function | ||
==Adult Dosing== | ==Adult Dosing== | ||
* | *hypertension: 10 - 40mg PO Qday, max 40mg/day | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* 1 month -16 year old: 0.1 - 0. | *1 month -16 year old: 0.1 - 0.5mg/kg/day PO divided q12 - 24h, max 40mg/day | ||
==Special Populations== | ==Special Populations== | ||
| Line 19: | Line 20: | ||
*Lactation: Probably Safe | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult: CrCl < 30, start 2. | **Adult: CrCl < 30, start 2.5mg qday, max 40mg q/day | ||
**Pediatric | **Pediatric creatinine Cl 10-50: decrease dose 25%, CrCl < 10: decrease dose 50% | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult: Not defined | **Adult: Not defined | ||
| Line 27: | Line 28: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
* | *history of angioedema | ||
* pregnancy | *pregnancy | ||
* caution if renal artery stenosis | *caution if renal artery stenosis | ||
* caution if severe CHF | *caution if severe CHF | ||
* caution if renal impairment | *caution if renal impairment | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
* angioedema | *angioedema | ||
* hypotension | *hypotension | ||
* hyperkalemia | *hyperkalemia | ||
* renal impairment | *renal impairment | ||
* hepatotoxicity | *hepatotoxicity | ||
* neutropenia | *neutropenia | ||
*pancreatitis | *pancreatitis | ||
* steven johnson syndrome | *steven johnson syndrome | ||
* fetal/neonatal harm | *fetal/neonatal harm | ||
* congenital malformations | *congenital malformations | ||
===Common=== | ===Common=== | ||
* dizziness | *dizziness | ||
* elevated Cr | *elevated Cr | ||
* headache | *headache | ||
*diarrhea | *diarrhea | ||
* hypotension | *hypotension | ||
* abdominal pain | *abdominal pain | ||
* hyperkalemia | *hyperkalemia | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 61: | Line 62: | ||
==See Also== | ==See Also== | ||
==References== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 06:32, 13 July 2017
Note: for the active metabolite available in IV, see Enalaprilat
General
- Type: ACE inhibitor
- Dosage Forms: 2.5, 5, 10, 20
- Common Trade Names: Vasotec, Epaned
General information:
- Doses > 40mg/day rarely more effective
- Decreased efficacy as monotherapy in Black patients
- Obtain Chem 10 if starting in ED to assess renal function
Adult Dosing
- hypertension: 10 - 40mg PO Qday, max 40mg/day
Pediatric Dosing
- 1 month -16 year old: 0.1 - 0.5mg/kg/day PO divided q12 - 24h, max 40mg/day
Special Populations
- Pregnancy Rating: D
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl < 30, start 2.5mg qday, max 40mg q/day
- Pediatric creatinine Cl 10-50: decrease dose 25%, CrCl < 10: decrease dose 50%
- Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- history of angioedema
- pregnancy
- caution if renal artery stenosis
- caution if severe CHF
- caution if renal impairment
Adverse Reactions
Serious
- angioedema
- hypotension
- hyperkalemia
- renal impairment
- hepatotoxicity
- neutropenia
- pancreatitis
- steven johnson syndrome
- fetal/neonatal harm
- congenital malformations
Common
- dizziness
- elevated Cr
- headache
- diarrhea
- hypotension
- abdominal pain
- hyperkalemia
Pharmacology
- Half-life: 12 hours
- Metabolism: Liver
- Excretion: urine, feces
- Mechanism of Action: inhibits angiotensin converting enzyme, interferes with conversion of angiotensin 1 to angiotensin 2